Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

14.47USD
6:44pm BST
Change (% chg)

$0.36 (+2.55%)
Prev Close
$14.11
Open
$14.22
Day's High
$14.92
Day's Low
$14.19
Volume
267,983
Avg. Vol
466,472
52-wk High
$49.87
52-wk Low
$11.50

Fair, Richard 

Mr. Richard A. Fair is Independent Director of the Company. Mr. Fair has served as President and Chief Executive Officer, and a member of the board of directors, of Bellicum Pharmaceuticals, Inc. since January 2017. Prior to joining Bellicum, he served as Senior Vice President, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc., a subsidiary of Roche Holding AG. From April 2006 to January 2014, Mr. Fair held other positions at Genentech, including Vice President, Global Product Strategy Hematology & Signaling, from November 2012 through December 2013, and Vice President, Sales & Marketing, Oral Oncolytics, from May 2010 to November 2012. Prior to Genentech, Mr. Fair held positions at Johnson & Johnson, a pharmaceutical and medical device company. Mr. Fair received his B.S. in computer science from the University of Michigan and his MBA from Columbia University. We believe Mr. Fair possesses specific attributes that qualify him to serve as a member of the company’s board of directors, including his years of leadership and commercial experience in the oncology industry.

Basic Compensation

Total Annual Compensation, USD 14,375
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 524,973
Fiscal Year Total, USD 539,348

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ginger Graham

357,479

Patrick Mahaffy

6,267,460

Gillian Ivers-Read

1,764,020

Daniel Muehl

1,509,580

Paul Gross

--

Ann Bozeman

--
As Of  31 Dec 2018